ZVSA
ZyVersa Therapeutics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 0
stock price surged significantly
EPS Beats Expectation
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About ZVSA
Zyversa Therapeutics, Inc.
A company that developing biopharmaceuticals for inflammatory and renal diseases
2200 N. Commerce Pkwy. Suite 208, Weston, Florida 33326
--
ZyVersa Therapeutics, Inc., was incorporated in Delaware on March 17, 2021. The Company is a clinical-stage biopharmaceutical company that utilizes proprietary technology to develop drugs for patients with chronic kidney disease or inflammatory diseases with high unmet medical needs.
Company Financials
EPS
ZVSA has released its 2024 Q3 earnings. EPS was reported at -2.43, versus the expected -1.60, missing expectations. The chart below visualizes how ZVSA has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
